Pharmaceuticals, Год журнала: 2025, Номер 18(5), С. 729 - 729

Опубликована: Май 15, 2025

This article profiles 27 innovative advancements in small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) 2024. These target various therapeutic areas including non-small cell lung cancer, advanced or metastatic breast glioma, relapsed refractory acute leukemia, urinary tract infection, Staphylococcus aureus bloodstream infections, nonalcoholic steatohepatitis, primary biliary cholangitis, Duchenne muscular dystrophy, hypertension, anemia due to chronic kidney disease, extravascular hemolysis, axillary hyperhidrosis, obstructive pulmonary severe alopecia areata, WHIM syndrome, Niemann–Pick disease type C, schizophrenia, supraventricular tachycardia, congenital adrenal hyperplasia, cystic fibrosis. Among these drugs, those with unique mechanisms of action designated as breakthrough therapies FDA represent a significant proportion, highlighting ongoing innovation. Notably, eight (including Rezdiffra®, Voydeya®, Iqirvo®, Voranigo®, Livdelzi®, Miplyffa®, Revuforj®, Crenessity®) are classified “first-in-class” have received therapy designation. agents not only exhibit distinct but also offer substantial improvements efficacy for patients compared prior options. offers comprehensive analysis action, clinical trials, drug design, synthetic methodologies related representative aiming provide crucial insights future pharmaceutical development.

Язык: Английский